Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
The Neo ALTO Study, combination therapy of lapatinib and trastuzumab and breast conservation surgery

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.12
Views: 4516

Dr Carmen Criscitiello - European Institute of Oncology, Milan, Italy

Dr Carmen Criscitiello talks to ecancer at ESMO 2012 in Vienna about a clinical study that showed the effects of lapatinib and trastuzumab combination therapy in breast cancer patients.

Results from the study showed an increase in improved pathological complete response; however, this did not translate into a higher rate of breast conservation surgery.

The study looked into what factors effect the decision for surgery and early results show that the largest factor for patients wanting to receive surgery is the preplanning of the procedure. 

Patients feel that this is the best treatment for them because it has already been decided, despite the effects of non-surgical treatment.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation